KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Common Equity: 2013-2025

Historic Common Equity for Xenon Pharmaceuticals (XENE) over the last 11 years, with Sep 2025 value amounting to $559.5 million.

  • Xenon Pharmaceuticals' Common Equity fell 29.87% to $559.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $559.5 million, marking a year-over-year decrease of 29.87%. This contributed to the annual value of $754.9 million for FY2024, which is 18.65% down from last year.
  • As of Q3 2025, Xenon Pharmaceuticals' Common Equity stood at $559.5 million, which was down 11.75% from $634.0 million recorded in Q2 2025.
  • Xenon Pharmaceuticals' 5-year Common Equity high stood at $927.9 million for Q4 2023, and its period low was $248.9 million during Q3 2021.
  • For the 3-year period, Xenon Pharmaceuticals' Common Equity averaged around $734.5 million, with its median value being $704.0 million (2025).
  • Per our database at Business Quant, Xenon Pharmaceuticals' Common Equity soared by 220.99% in 2021 and then declined by 29.87% in 2025.
  • Quarterly analysis of 5 years shows Xenon Pharmaceuticals' Common Equity stood at $550.0 million in 2021, then skyrocketed by 31.17% to $721.5 million in 2022, then increased by 28.61% to $927.9 million in 2023, then fell by 18.65% to $754.9 million in 2024, then decreased by 29.87% to $559.5 million in 2025.
  • Its Common Equity was $559.5 million in Q3 2025, compared to $634.0 million in Q2 2025 and $704.0 million in Q1 2025.